Back to mobile site
Get it on Google Play

Aclarion revises CLARITY trial criteria after missing Q4 enrollment goal

October 8, 2026 7:01 AM EDT Send to a Friend
Aclarion, Inc. (Nasdaq: ACON, ACONW) announced it has broadened the enrollment criteria for its pivotal CLARITY clinical trial after enrollment ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login